Ultraviolet A1 Phototherapy for Fibrosing Conditions

Thilo Gambichler, Lutz Schmitz, Thilo Gambichler, Lutz Schmitz

Abstract

In this article we describe efficacy and safety aspects of ultraviolet A1 (UV-A1) phototherapy in fibrosing conditions. UV-A1 is a specific phototherapeutic modality that is defined by a selective spectral range (340-400 nm). UV-A1 includes distinct modes of action qualifying this method for therapy of a variety of conditions, in particular fibrosing skin diseases. Concerning efficacy of UV-A1 phototherapy in fibrosing conditions, the best evidence obtained from randomized controlled trials exists for localized scleroderma. Moreover, fibrosing disorders such as lichen sclerosus and graft-vs.-host disease can be treated successfully by means of UV- A1. Regarding the optimal dosage regimen medium-dose UV-A1 seems to be linked to the best benefit/risk ratio. Possible acute adverse events of UV-A1 phototherapy include erythema and provocation of photodermatoses. Skin ageing and skin cancer formation belong to the chronic adverse events that may occur after long-term UV-A1 phototherapy.

Keywords: UV-A1; UVA1; fibrosis; irradiation; phototherapy; sclerosis; ultraviolet A1.

References

    1. Plewig G, Hofmann C, Braun-Falco O, Nath G, Kreitmair A. A new apparatus for the delivery of high intensity UVA and UVA+UVB irradiation, and some dermatological applications. Br J Dermatol. (1978) 98:15–24. 10.1111/j.1365-2133.1978.tb07328.x
    1. Mutzhas MF, Holzle E, Hofmann C, Plewig G. A new apparatus with high radiation energy between 320-460 nm: physical description and dermatological applications. J Invest Dermatol. (1981) 76:42–7. 10.1111/1523-1747.ep12524813
    1. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol. (2000) 25:552–8. 10.1046/j.1365-2230.2000.00700.x
    1. Baron ED, Stevens SR. Phototherapy for cutaneous T-cell lymphoma. Dermatol Ther. (2003) 16:303–10. 10.1111/j.1396-0296.2003.01642.x
    1. Dawe RS. Ultraviolet A1 phototherapy. Br J Dermatol. (2003) 148:626–37. 10.1046/j.1365-2133.2003.05261.x
    1. Pavel S. Light therapy (with UVA-1) for SLE patients: is it a good or bad idea? Rheumatology (2006) 45:653–5. 10.1093/rheumatology/kel063
    1. Tuchinda C, Kerr HA, Taylor CR, Jacobe H, Bergamo BM, Elmets C, et al. . UVA1 phototherapy for cutaneous diseases: an experience of 92 cases in the United States. Photodermatol Photoimmunol Photomed. (2006) 22:247–53. 10.1111/j.1600-0781.2006.00245.x
    1. Meduri NB, Vandergriff T, Rasmussen H, Jacobe H. Phototherapy in the management of atopic dermatitis: a systematic review. Photodermatol Photoimmunol Photomed. (2007) 23:106–12. 10.1111/j.1600-0781.2007.00291.x
    1. Jacobe HT, Cayce R, Nguyen J. UVA1 phototherapy is effective in darker skin: a review of 101 patients of Fitzpatrick skin types I-V. Br J Dermatol. (2008) 159:691–6. 10.1111/j.1365-2133.2008.08672.x
    1. Kroft EB, Berkhof NJ, van de Kerkhof PC, Gerritsen RM, de Jong EM. Ultraviolet A phototherapy for sclerotic skin diseases: a systematic review. J Am Acad Dermatol. (2008a) 59:1017–30. 10.1016/j.jaad.2008.07.042
    1. Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases. Photodermatol Photoimmunol Photomed. (2008) 24:19–23. 10.1111/j.1600-0781.2008.00328.x
    1. Gambichler T. Management of atopic dermatitis using photo(chemo)therapy. Arch Dermatol Res. (2009) 301:197–203. 10.1007/s00403-008-0923-5
    1. Suh KS, Kang JS, Baek JW, Kim TK, Lee JW, Jeon YS, et al. . Efficacy of ultraviolet A1 phototherapy in recalcitrant skin diseases. Ann Dermatol. (2010) 22:1–8. 10.5021/ad.2010.22.1.1
    1. York NR, Jacobe HT. UVA1 phototherapy: a review of mechanism and therapeutic application. Int J Dermatol. (2010) 49:623–30. 10.1111/j.1365-4632.2009.04427.x
    1. Gambichler T, Terras S, Kreuter A. Treatment regimens, protocols, dosage, and indications for UVA1 phototherapy: facts and controversies. Clin Dermatol. (2013) 31:438–54. 10.1016/j.clindermatol.2013.01.011
    1. Lim HW, Hönigsmann H, Hawk JLM. Photodermatology. New York, NY: Informa Healthcare USA Inc; (2007).
    1. Brem R, Karran P. Multiple forms of DNA damage caused by UVA photoactivation of DNA 6-thioguanine. Photochem Photobiol. (2011) 88:5–13. 10.1111/j.1751-1097.2011.01043.x
    1. Calzavara-Pinton PG, Caravello S. A practical approach to the initial dose and subsequent increments for ultraviolet A1 phototherapy. Br J Dermatol. (2017) 177:19–20. 10.1111/bjd.15486
    1. Gambichler T, Majert J, Pljakic A, Rooms I, Wolf P. Determination of the minimal erythema dose for ultraviolet A1 radiation. Br J Dermatol. (2017) 177:238–44. 10.1111/bjd.15245
    1. Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. Dose-response and time-course characteristics of UV-A1 erythema. Arch Dermatol. (2005) 141:1549–55. 10.1001/archderm.141.12.1549
    1. Eadie E, Ibbotson SH, Dawe RS. Irradiance, as well as body site and timing of readings, is important in determining ultraviolet A minimal erythema dose. Br J Dermatol. (2018) 178:297–8. 10.1111/bjd.16005
    1. Gambichler T, Wolf P. Irradiance, as well as body site and timing of readings, is important in determining ultraviolet A minimal erythemal dose: reply from the authors. Br J Dermatol. (2018) 178:298–9. 10.1111/bjd.16044
    1. Kerr AC, Ferguson J, Attili SK, Beattie PE, Coleman AJ, Dawe RS, et al. . Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clin Exp Dermatol. (2012) 37:219–26. 10.1111/j.1365-2230.2011.04256.x
    1. Stege H, Berneburg M, Humke S, Klammer M, Grewe M, Grether-Beck S, et al. . High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol. (1997) 36(6 Pt 1):938–44. 10.1016/S0190-9622(97)80277-0
    1. Ju M, Chen K, Chang B, Gu H. UVA1 irradiation inhibits fibroblast proliferation and alleviates pathological changes of scleroderma in a mouse model. J Biomed Res. (2012) 26:135–42. 10.1016/S1674-8301(12)60023-2
    1. Karpec D, Rudys R, Leonaviciene L, Mackiewicz Z, Bradunaite R, Kirdaite G, et al. . The impact of high-dose narrowband ultraviolet A1 on dermal thickness, collagen and matrix- metalloproteinases in animal model of scleroderma. J Photochem Photobiol B. (2017a) 173:448–55. 10.1016/j.jphotobiol.2017.06.021
    1. Karpec D, Rudys R, Leonaviciene L, Mackiewicz Z, Bradunaite R, Kirdaite G, et al. . The safety and efficacy of light emitting diodes-based ultraviolet A1 phototherapy in bleomycin- induced scleroderma in mice. Adv Med Sci. (2017b) 63:152–9. 10.1016/j.advms.2017.09.001
    1. Kerscher M, Dirschka T, Volkenandt M. Treatment of localised scleroderma by UVA1 phototherapy. Lancet (1995) 346:1166. 10.1016/S0140-6736(95)91843-4
    1. Gruss CJ, Von Kobyletzki G, Behrens-Williams SC, Lininger J, Reuther T, Kerscher M, et al. . Effects of low dose ultraviolet A-1 phototherapy on morphea. Photodermatol Photoimmunol Photomed. (2001) 17:149–55. 10.1034/j.1600-0781.2001.170401.x
    1. Camacho NR, Sanchez JE, Martin RF, Gonzalez JR, Sanchez JL. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol. (2001) 45:697–9. 10.1067/mjd.2001.117735
    1. de Rie MA, Enomoto DN, de Vries HJ, Bos JD. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology (2003) 207:298–301. 10.1159/000073093
    1. Kreuter A, Hyun J, Stucker M, Sommer A, Altmeyer P, Gambichler T. A randomized controlled study of low-dose UVA1, medium-dose UVA1, and narrowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. (2006c) 54:440–7. 10.1016/j.jaad.2005.11.1063
    1. Sator PG, Radakovic S, Schulmeister K, Honigsmann H, Tanew A. Medium-dose is more effective than low-dose ultraviolet A1 phototherapy for localized scleroderma as shown by 20-MHz ultrasound assessment. J Am Acad Dermatol. (2009) 60:786–91. 10.1016/j.jaad.2008.12.013
    1. Vasquez R, Jabbar A, Khan F, Buethe D, Ahn C, Jacobe H. Recurrence of morphea after successful ultraviolet A1 phototherapy: a cohort study. J Am Acad Dermatol. (2014) 70:481–88. 10.1016/j.jaad.2013.10.018
    1. Su O, Onsun N, Onay HK, Erdemoglu Y, Ozkaya DB, Cebeci F, et al. . Effectiveness of medium-dose ultraviolet A1 phototherapy in localized scleroderma. Int J Dermatol. (2011) 50:1006–13. 10.1111/j.1365-4632.2010.04843.x
    1. Andres C, Kollmar A, Mempel M, Hein R, Ring J, Eberlein B. Successful ultraviolet A1 phototherapy in the treatment of localized scleroderma: a retrospective and prospective study. Br J Dermatol. (2009) 162:445–7. 10.1111/j.1365-2133.2009.09438.x
    1. Pereira N, Santiago F, Oliveira H, Figueiredo A. Low-dose UVA(1) phototherapy for scleroderma: what benefit can we expect? J Eur Acad Dermatol Venereol. (2011) 26:619–26. 10.1111/j.1468-3083.2011.04137.x
    1. Gruss C, Stucker M, Kobyletzki G, Schreiber D, Altmeyer P, Kerscher M. Low dose UVA1 phototherapy in disabling pansclerotic morphoea of childhood. Br J Dermatol. (1997) 136:293–4. 10.1111/j.1365-2133.1997.tb14925.x
    1. Silber S. A new and rapid scoring system to assess the scientific evidence from clinical trials. J Interv Cardiol. (2006) 19:485–92. 10.1111/j.1540-8183.2006.00205.x
    1. von Kobyletzki G, Uhle A, Pieck C, Hoffmann K, Altmeyer P. Acrosclerosis in patients with systemic sclerosis responds to low-dose UV-A1 phototherapy. Arch Dermatol. (2000) 136:275–6. 10.1001/archderm.136.2.275
    1. Morita A, Kobayashi K, Isomura I, Tsuji T, Krutmann J. Ultraviolet A1 (340-400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol. (2000) 43:670–4. 10.1067/mjd.2000.105165
    1. Sawada H, Isogai Z, Morita A. Altered decorin expression of systemic sclerosis by UVA1 (340-400 nm) phototherapy: immunohistochemical analysis of 3 cases. BMC Dermatol. (2003) 3:2. 10.1186/1471-5945-3-2
    1. Kreuter A, Breuckmann F, Uhle A, Brockmeyer N, Von Kobyletzki G, Freitag M, et al. . Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol. (2004) 50:740–7.
    1. Rose RF, Turner D, Goodfield MJ, Goulden V. Low-dose UVA1 phototherapy for proximal and acral scleroderma in systemic sclerosis. Photodermatol Photoimmunol Photomed. (2009) 25:153–5. 10.1111/j.1600-0781.2009.00422.x
    1. Durand F, Staumont D, Bonnevalle A, Hachulla E, Hatron PY, Thomas P. Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis. Photodermatol Photoimmunol Photomed. (2007) 23:215–21. 10.1111/j.1600-0781.2007.00308.x
    1. Tewari A, Garibaldinos T, Lai-Cheong J, Groves R, Sarkany R, Branislav Novakovic L. Successful treatment of microstomia with UVA1 phototherapy in systemic sclerosis. Photodermatol Photoimmunol Photomed. (2011) 27:113–4. 10.1111/j.1600-0781.2011.00570.x
    1. Connolly KL, Griffith JL, McEvoy M, Lim HW. Ultraviolet A1 phototherapy beyond morphea: experience in 83 patients. Photodermatol Photoimmunol Photomed. (2015) 31:289–95. 10.1111/phpp.12185
    1. Comte C, Bessis D, Picot E, Peyron JL, Guillot B, Dereure O. [Treatment of connective tissue disorder-related acral syndromes using UVA-1 phototherapy. An open study of 11 cases]. Ann Dermatol Venereol. (2009) 136:323–9. 10.1016/j.annder.2008.12.022
    1. Beattie PE, Dawe RS, Ferguson J, Ibbotson SH. UVA1 phototherapy for genital lichen sclerosus. Clin Exp Dermatol. (2006) 31:343–7. 10.1111/j.1365-2230.2006.02082.x
    1. Terras S, Gambichler T, Moritz RK, Stucker M, Kreuter A. UV-A1 phototherapy vs clobetasol propionate, 0.05%, in the treatment of vulvar lichen sclerosus: a randomized clinical trial. JAMA Dermatol. (2014). 150:621–7. 10.1001/jamadermatol.2013.7733
    1. Gambichler T, Terras S, Kreuter A, Skrygan M. Altered global methylation and hydroxymethylation status in vulvar lichen sclerosus: further support for epigenetic mechanisms. Br J Dermatol. (2014) 170:687–93. 10.1111/bjd.12702
    1. Grundmann-Kollmann M, Behrens S, Gruss C, Gottlober P, Peter RU, Kerscher M. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. J Am Acad Dermatol. (2000) 42(1 Pt 1), 134–6. 10.1016/S0190-9622(00)90023-9
    1. Stander H, Schiller M, Schwarz T. UVA1 therapy for sclerodermic graft-versus-host disease of the skin. J Am Acad Dermatol. (2002) 46:799–800. 10.1067/mjd.2002.121352
    1. Calzavara Pinton P, Porta F, Izzi T, Venturini M, Capezzera R, Zane C, et al. Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. Haematologica (2003) 88:1169–75.
    1. Schlaak M, Schwind S, Wetzig T, Maschke J, Treudler R, Basara N, et al. . UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transpl. (2010) 45:1741–8. 10.1038/bmt.2010.230
    1. Tran KT, Prather HB, Cockerell CJ, Jacobe H. UV-A1 therapy for nephrogenic systemic fibrosis. Arch Dermatol. (2009) 145:1170–4. 10.1001/archdermatol.2009.245
    1. Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, et al. . Outcome measurements in scleroderma: results from a delphi exercise. J Rheumatol. (2007) 34:501–9.
    1. Asawanonda P, Khoo LS, Fitzpatrick TB, Taylor CR. UV-A1 for keloid. Arch Dermatol. (1999) 135:348–9. 10.1001/archderm.135.3.348
    1. Hannuksela-Svahn A, Grandal OJ, Thorstensen T, Christensen OB. UVA1 for treatment of keloids. Acta Derm Venereol. (1999) 79:490. 10.1080/000155599750010076
    1. Janiga JJ, Ward DH, Lim HW. UVA-1 as a treatment for scleredema. Photodermatol Photoimmunol Photomed. (2004) 20:210–1. 10.1111/j.1600-0781.2004.00106.x
    1. Kroft EB, van de Kerkhof PC, Gerritsen MJ, de Jong EM. Period of remission after treatment with UVA-1 in sclerodermic skin diseases. J Eur Acad Dermatol Venereol. (2008b) 22:839–44. 10.1111/j.1468-3083.2007.02576.x
    1. Silny W, Osmola-Mankowska A, Czarnecka-Operacz M, Zaba R, Danczak-Pazdrowska A, Marciniak A. Eosinophilic fascitis: a report of two cases treated with ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed. (2009) 25:325–7. 10.1111/j.1600-0781.2009.00463.x
    1. Polat M, Kaya H, Sahin A. A new approach in the treatment of keloids: UVA-1 Laser. Photomed Laser Surg. (2016) 34:130–3. 10.1089/pho.2015.4046
    1. Wang F, Garza LA, Cho S, Kafi R, Hammerberg C, Quan T, et al. . Effect of increased pigmentation on the antifibrotic response of human skin to UV-A1 phototherapy. Arch Dermatol. (2008) 144:851–8. 10.1001/archderm.144.7.851
    1. Kreuter A, Gambichler T. UV-A1 phototherapy for sclerotic skin diseases: implications for optimizing patient selection and management. Arch Dermatol. (2008) 144:912–6. 10.1001/archderm.144.7.912
    1. Yin L, Yamauchi R, Tsuji T, Krutmann J, Morita A. The expression of matrix metalloproteinase-1 mRNA induced by ultraviolet A1 (340-400 nm) is phototherapy relevant to the glutathione (GSH) content in skin fibroblasts of systemic sclerosis. J Dermatol. (2003) 30:173–80. 10.1111/j.1346-8138.2003.tb00368.x
    1. Breuckmann F, Gambichler T, Altmeyer P, Kreuter A. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol. (2004) 4:11. 10.1186/1471-5945-4-11
    1. Kreuter A, Hyun J, Skrygan M, Sommer A, Bastian A, Altmeyer P, et al. . Ultraviolet A1- induced downregulation of human beta-defensins and interleukin-6 and interleukin-8 correlates with clinical improvement in localized scleroderma. Br J Dermatol. (2006a) 155:600–7. 10.1111/j.1365-2133.2006.07391.x
    1. Kreuter A, Hyun J, Skrygan M, Sommer A, Tomi NS, Breuckmann F, et al. . Ultraviolet A1 phototherapy decreases inhibitory SMAD7 gene expression in localized scleroderma. Arch Dermatol Res. (2006b) 298:265–72. 10.1007/s00403-006-0695-8
    1. Gambichler T, Skrygan M, Tomi NS, Altmeyer P, Kreuter A. Differential expression of decorin in localized scleroderma following ultraviolet-A1 irradiation. J Am Acad Dermatol. (2007a) 56:956–9. 10.1016/j.jaad.2006.10.961
    1. Gambichler T, Skrygan M, Tomi NS, Breuksch S, Altmeyer P, Kreuter A. Significant downregulation of transforming growth factor-beta signal transducers in human skin following ultraviolet-A1 irradiation. Br J Dermatol. (2007b) 156:951–6. 10.1111/j.1365-2133.2007.07802.x
    1. Richer V, Lui H. Cross-sectional evaluation of acute adverse reactions during ultraviolet A1 phototherapy. Br J Dermatol. (2017) 177:258–9. 10.1111/bjd.15319
    1. Besaratinia A, Kim SI, Bates SE, Pfeifer GP. Riboflavin activated by ultraviolet A1 irradiation induces oxidative DNA damage-mediated mutations inhibited by vitamin C. Proc Natl Acad Sci USA. (2007) 104:5953–8. 10.1073/pnas.0610534104
    1. Wang F, Smith NR, Tran BA, Kang S, Voorhees JJ, Fisher GJ. Dermal damage promoted by repeated low-level UV-A1 exposure despite tanning response in human skin. JAMA Dermatol. (2014) 150:401–6. 10.1001/jamadermatol.2013.8417
    1. Gambichler T, Al-Muhammadi R, Boms S. Immunologically mediated photodermatoses: diagnosis and treatment. Am J Clin Dermatol. (2009) 10:169–80. 10.2165/00128071-200910030-00003
    1. Aljasser MI, Lui H, Ball NJ, Kalia S. Persistent polymorphous light eruption after ultraviolet A1 phototherapy. Photodermatol Photoimmunol Photomed. (2013) 29:52–4. 10.1111/phpp.12020
    1. Damian DL, Matthews YJ, Phan TA, Halliday GM. An action spectrum for ultraviolet radiation-induced immunosuppression in humans. Br J Dermatol. (2011) 164:657–9. 10.1111/j.1365-2133.2010.10161.x
    1. Park J, Halliday GM, Surjana D, Damian DL. Nicotinamide prevents ultraviolet radiation-induced cellular energy loss. Photochem Photobiol. (2010) 86:942–8. 10.1111/j.1751-1097.2010.00746.x
    1. Halliday GM, Byrne SN, Damian DL. Ultraviolet A radiation: its role in immunosuppression and carcinogenesis. Semin Cutan Med Surg. (2011) 30:214–21. 10.1016/j.sder.2011.08.002
    1. Tewari A, Sarkany RP, Young AR. UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo. J Invest Dermatol. (2012) 132:394–400. 10.1038/jid.2011.283
    1. Brem R, Daehn I, Karran P. Efficient DNA interstrand crosslinking by 6-thioguanine and UVA radiation. DNA Repair (2011) 10:869–76. 10.1016/j.dnarep.2011.05.010

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe